Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive — Trabectedin First Line Therapy In Unfit Sarcoma Study
Citation(s)
SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES